NZ598067A - Benzazepine derivatives useful as vasopressin antagonists - Google Patents

Benzazepine derivatives useful as vasopressin antagonists

Info

Publication number
NZ598067A
NZ598067A NZ598067A NZ59806708A NZ598067A NZ 598067 A NZ598067 A NZ 598067A NZ 598067 A NZ598067 A NZ 598067A NZ 59806708 A NZ59806708 A NZ 59806708A NZ 598067 A NZ598067 A NZ 598067A
Authority
NZ
New Zealand
Prior art keywords
derivatives useful
vasopressin antagonists
benzazepine derivatives
methyl
compound
Prior art date
Application number
NZ598067A
Other languages
English (en)
Inventor
Kazumi Kondo
Yasuhiro Menjo
Takahiro Tomoyasu
Shin Miyamura
Yuso Tomohira
Takakuni Matsuda
Keigo Yamada
Yusuke Kato
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NZ598067A publication Critical patent/NZ598067A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ598067A 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists NZ598067A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007167207 2007-06-26
NZ581723A NZ581723A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Publications (1)

Publication Number Publication Date
NZ598067A true NZ598067A (en) 2012-12-21

Family

ID=39773045

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ598067A NZ598067A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists
NZ598064A NZ598064A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists
NZ581723A NZ581723A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ598064A NZ598064A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists
NZ581723A NZ581723A (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Country Status (27)

Country Link
US (3) US8669229B2 (cg-RX-API-DMAC7.html)
EP (3) EP2170831B1 (cg-RX-API-DMAC7.html)
JP (3) JP5653043B2 (cg-RX-API-DMAC7.html)
KR (1) KR101487201B1 (cg-RX-API-DMAC7.html)
CN (3) CN103342679A (cg-RX-API-DMAC7.html)
AR (1) AR067176A1 (cg-RX-API-DMAC7.html)
AT (1) ATE545633T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008269918B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813768A2 (cg-RX-API-DMAC7.html)
CA (1) CA2690335A1 (cg-RX-API-DMAC7.html)
CO (1) CO6160295A2 (cg-RX-API-DMAC7.html)
CY (3) CY1113519T1 (cg-RX-API-DMAC7.html)
DK (3) DK2374797T3 (cg-RX-API-DMAC7.html)
ES (3) ES2431515T3 (cg-RX-API-DMAC7.html)
HR (3) HRP20120310T1 (cg-RX-API-DMAC7.html)
IL (1) IL202561A0 (cg-RX-API-DMAC7.html)
MY (3) MY150941A (cg-RX-API-DMAC7.html)
NZ (3) NZ598067A (cg-RX-API-DMAC7.html)
PH (2) PH12012501363A1 (cg-RX-API-DMAC7.html)
PL (3) PL2374797T3 (cg-RX-API-DMAC7.html)
PT (3) PT2374797E (cg-RX-API-DMAC7.html)
RU (1) RU2471784C2 (cg-RX-API-DMAC7.html)
SG (2) SG182231A1 (cg-RX-API-DMAC7.html)
SI (3) SI2170831T1 (cg-RX-API-DMAC7.html)
TW (1) TWI459947B (cg-RX-API-DMAC7.html)
UA (1) UA98966C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009001968A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
JP5656399B2 (ja) * 2008-12-26 2015-01-21 大塚製薬株式会社 医薬及び医薬製剤
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
EA022253B1 (ru) * 2009-10-26 2015-11-30 Оцука Фармасьютикал Ко., Лтд. Соединение бензазепина и его применения
GB201105537D0 (en) 2011-03-31 2011-05-18 Vantia Ltd New process
CN102260213B (zh) * 2011-05-31 2013-05-15 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
TW201427669A (zh) * 2012-12-28 2014-07-16 Otsuka Pharma Co Ltd 包含有光學活性托伐普坦（ｔｏｌｖａｐｔａｎ）之可注射的補給配方，及其製造方法
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
WO2019003433A1 (ja) * 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
KR20230143165A (ko) 2021-02-10 2023-10-11 상하이 센후이 메디슨 컴퍼니 리미티드 벤즈아제핀 화합물, 이의 제조 방법 및 이의 약학적 용도
CN113112528A (zh) * 2021-04-26 2021-07-13 中南财经政法大学 异常行为监控方法、装置、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045478A (en) * 1986-03-03 1991-09-03 Becton Dickinson And Company Vesicles and use thereof in an assay
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
AU657424B2 (en) 1992-07-02 1995-03-09 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
TW270927B (cg-RX-API-DMAC7.html) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
GB9726695D0 (en) 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
UA72749C2 (en) * 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
EP2308863A1 (en) 2000-05-15 2011-04-13 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
EP1812039A1 (en) 2004-11-02 2007-08-01 New River Pharmaceuticals Inc. Prodrugs of ribavirin with improved hepatic delivery
US20100004206A1 (en) * 2005-12-27 2010-01-07 Makoto Komatsu Water-soluble benzoazepine compound and its pharmaceutical composition
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Also Published As

Publication number Publication date
ES2460018T3 (es) 2014-05-13
CY1114491T1 (el) 2016-10-05
SG182231A1 (en) 2012-07-30
EP2170831A1 (en) 2010-04-07
UA98966C2 (ru) 2012-07-10
US20140024619A1 (en) 2014-01-23
CA2690335A1 (en) 2008-12-31
ATE545633T1 (de) 2012-03-15
TW200911271A (en) 2009-03-16
PT2374797E (pt) 2014-05-02
EP2374798A1 (en) 2011-10-12
EP2374797A1 (en) 2011-10-12
CN103342679A (zh) 2013-10-09
PT2170831E (pt) 2012-04-13
DK2374797T3 (da) 2014-05-12
DK2170831T3 (da) 2012-05-21
PH12012501363A1 (en) 2014-04-28
JP5689195B2 (ja) 2015-03-25
KR101487201B1 (ko) 2015-01-28
CY1113519T1 (el) 2016-06-22
KR20100040873A (ko) 2010-04-21
JP5653043B2 (ja) 2015-01-14
RU2010102229A (ru) 2011-08-10
EP2374798B1 (en) 2013-09-04
DK2374798T3 (da) 2013-10-07
PL2170831T3 (pl) 2012-08-31
HK1163660A1 (en) 2012-09-14
HRP20140501T1 (hr) 2014-07-04
US20140024640A1 (en) 2014-01-23
SI2170831T1 (sl) 2012-04-30
BRPI0813768A2 (pt) 2014-12-30
EP2170831B1 (en) 2012-02-15
SG182230A1 (en) 2012-07-30
ES2431515T3 (es) 2013-11-26
SI2374797T1 (sl) 2014-05-30
MY152805A (en) 2014-11-28
EP2374797B1 (en) 2014-03-26
US20110071084A1 (en) 2011-03-24
PT2374798E (pt) 2013-11-05
SI2374798T1 (sl) 2013-10-30
HK1141994A1 (en) 2010-11-26
CN101687805A (zh) 2010-03-31
HK1163077A1 (en) 2012-09-07
MY148312A (en) 2013-03-29
CO6160295A2 (es) 2010-05-20
CN103342680A (zh) 2013-10-09
AU2008269918B2 (en) 2012-12-06
MY150941A (en) 2014-03-14
TWI459947B (zh) 2014-11-11
IL202561A0 (en) 2010-06-30
PL2374798T3 (pl) 2014-01-31
HRP20131095T1 (hr) 2014-01-03
NZ581723A (en) 2012-03-30
PH12012501362A1 (en) 2014-04-28
AR067176A1 (es) 2009-09-30
ES2380085T3 (es) 2012-05-08
AU2008269918A1 (en) 2008-12-31
NZ598064A (en) 2013-04-26
US9073868B2 (en) 2015-07-07
US8785386B2 (en) 2014-07-22
RU2471784C2 (ru) 2013-01-10
JP5893085B2 (ja) 2016-03-23
HRP20120310T1 (hr) 2012-06-30
PL2374797T3 (pl) 2014-08-29
WO2009001968A1 (en) 2008-12-31
US8669229B2 (en) 2014-03-11
CY1115226T1 (el) 2017-01-04
JP2010531293A (ja) 2010-09-24
JP2014205703A (ja) 2014-10-30
JP2014208680A (ja) 2014-11-06

Similar Documents

Publication Publication Date Title
NZ598067A (en) Benzazepine derivatives useful as vasopressin antagonists
GEP20084465B (en) Beta-crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it
GEP20084467B (en) Gamma crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing it
GEP20084468B (en) Gamma-d crystalline form of ivabradin hydrochloride, process for its preparation and pharmaceutical compositions containing it
TW200833328A (en) 2-aza-bicyclo[3.1.0]hexane derivatives
ZA200300403B (en) Fused azepine derivatives and their use as antidiuretic agents.
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
MY141194A (en) Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts
WO2009016564A3 (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2010030704A3 (en) Antibacterial aminoglycoside analogs
WO2011044501A3 (en) Antibacterial aminoglycoside analogs
MY178894A (en) Therapeutic compositions containing macitentan
MX2009006288A (es) Nuevo procedimiento de sintesis de 7,8-dimetoxi-1,3-dihidro-2h-3-b enzazepin-2-ona, y aplicacion en la sintesis de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
AU2003210477A8 (en) Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
WO2010124042A3 (en) Modulators of 5-ht receptors and methods of use thereof
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
MX2009001578A (es) Lactamas terapeuticas.
WO2009145357A8 (en) Benzo [1, 4] diazepines substituted at the 1-position by a ring, for use as antidepressants
HUP0301590A3 (en) Nonpeptide substituted spirobenzoazepines as vasopressin antagonists, pharmaceutical compositions containing them and their preparation
WO2007017728A3 (en) Novel heterocyclic compounds
MY140904A (en) Process for the synthesis of 1,3,4,5-tetrahydro-2h-3-benzazepin-2-one compounds, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY136474A (en) DIBENZO [b,f] AZEPINE DERIVATIVES AND THEIR PREPARATION
WO2009137130A3 (en) Antibacterial fluoroquinolone analogs

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 JUN 2015 BY AJ PARK

Effective date: 20130513

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 JUN 2016 BY CPA GLOBAL

Effective date: 20150516

LAPS Patent lapsed